H.C. Wainwright analyst Joseph Pantginis downgraded Aravive to Neutral from Buy without a price target after the company announced that the registration-directed Phase 3 trial of the company’s GAS6-AXL pathway inhibitor, batiraxcept, in combination with chemotherapy for platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival. The analyst believes the perceived risk for the company’s renal cell and pancreatic programs has increased significantly.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARAV: